Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?

J Alzheimers Dis. 2010;22(2):345-55. doi: 10.3233/JAD-2010-100711.

Abstract

Senile plaques and cerebral amyloid angiopathy in Alzheimer's disease (AD) patients not only consist of the amyloid-β protein (Aβ), but also contain many different Aβ-associated factors, such as heparan sulfate proteoglycans, apolipoproteins, and complement factors. These factors may all influence Aβ deposition, aggregation, and clearance and therefore seem important in the development of human Aβ deposits. To study AD pathology and test new therapeutic agents, many different mouse models have been created. By transgenic expression of the amyloid-β protein precursor, frequently in combination with other transgenes, these animals develop Aβ deposits that morphologically resemble their human counterparts. Whether this resemblance also applies to the presence of Aβ-associated factors is largely unclear. In this review, the co-deposition of factors known to associate with human Aβ deposits is summarized for several different AD mouse models.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Apolipoproteins / metabolism*
  • Complement System Proteins / metabolism*
  • Disease Models, Animal
  • Heparan Sulfate Proteoglycans / metabolism*
  • Humans
  • Mice

Substances

  • Amyloid beta-Peptides
  • Apolipoproteins
  • Heparan Sulfate Proteoglycans
  • Complement System Proteins